A multicentre phase III/IV study, of the effects of risedronate sodium
(ACTONEL™, 35 mg/week, oral) on bone, in postmenopausal women, with
hormone-receptor-positive early breast cancer, treated with anastrozole
(ARIMIDEX™, 1 mg/day oral) with either high-risk of fragility fracture
(open-label, non-comparative stratum), or moderate-risk of fragility fracture
(randomised, double-blind stratum), and of the effects of anastrozole
(ARIMIDEX™, 1 mg/day oral) on bone, in postmenopausal women, with
hormone-receptor-positive early breast cancer, and low-risk of fragility
fracture (open-label, non-comparative stratum)